Loading Page
Dr. Brian H. Kushner, MD is a physician provider in New York, NY specializing in physician, pediatric oncology, oncology (cancer care) and general pediatrics. He graduated from Johns Hopkins University in 1976 and has 50 years of experience. Dr. Brian H. Kushner, MD is affiliated with Memorial Sloan Kettering Cancer Center.
Dr. Brian H. Kushner, MD graduated from Johns Hopkins University in 1976. He completed residency at New York-Presbyterian Hospital. He is certified by the Board Certification: Pediatrics and has a state license in New York.
Medical School: Johns Hopkins University (1976)
Residency: New York-Presbyterian Hospital
Board Certification: Board Certification: Pediatrics
Licensed In: New York
Dr. Brian H. Kushner, MD appears to accept the following insurance providers: Horizon Blue Cross Blue Shield New Jersey (PPO), Magnacare, Emblem, Oscar, Fidelis Medicare Advantage, NYC Medicare Advantage Plus for City Employees, Healthsmart, United Healthcare, Aetna, Tricare, Oxford, Straight NY Medicaid, Healthfirst, Cigna, Qualcare, MVP, Connecticare, Healthfirst Medicare Advantage, First Health, Multiplan/Beech Street/PHCS, World Trade Center Health Program (WTC), Blue Cross Blue Shield states outside of NY/NJ, Empire Essential, Non-Participating Plans with Out of Network Benefits, Blue Cross Blue Shield New York, Blue Cross Blue Shield Federal Employee Program, UMR, Medicare Part A&B (traditional Medicare), Carrum Health and Blue Cross Health Plus.
According to our sources, Dr. Brian H. Kushner, MD accepts the following insurance providers:
Dr. Brian H. Kushner, MD has an exceptional overall rating with an average of 5.0 out of 5 stars based on 26 ratings. We collect ratings and reviews of Dr. Brian H. Kushner, MD from all over the web to help you find the right in New York, NY.
Dr. Brian H. Kushner, MD has received 1 research payments totaling $4,300.
I am a pediatric oncologist whose specialty is neuroblastoma. We’ve made significant progress in improving the outlook for many children newly diagnosed with this challenging disease, and we are now able to achieve the best cure rates. For those whose disease returns, we are devising new approaches that are showing encouraging results.
